Tricida, Inc. is a pharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 57 full-time employees. The company went IPO on 2018-06-28. The firm is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. The company is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.

Industry: Pharmaceutical Preparations Peers: ANI Pharmaceuticals Inc Atea Pharmaceuticals Inc Tvardi Therapeutics Inc Collegium Pharmaceutical Inc Edgewise Therapeutics Inc Nektar Therapeutics Johnson & Johnson Nuvation Bio Inc Phibro Animal Health Corp